Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Jee Soo Kim, M.D., Ph.D.
- Phone Number: 82-2-3410-3479
- Email: js0507.kim@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
Contact:
- Jee Soo Kim, M.D., Ph.D.
- Phone Number: 82-2-3410-3479
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- papillary carcinoma of thyroid (less than 4cm)
- no evidence of lymph node metastasis in preoperative work-up result
- the patients who accept this study
Exclusion Criteria:
- large thyroid cancer( > 4cm)
- morbid
- anticoagulation agent usage
- endoscopic or robotic thyroid operation
- evidence of lymph node metastasis or extrathyroidal extension in preoperative US and CT scan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: C group
Routine central neck dissection
|
Level VI neck node dissection during thyroid operation
|
|
No Intervention: N group
No central neck node dissection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Is routine neck node dissection necessary in micro PTC?
Time Frame: Until 5 year follow-up. (Dec. 2016)
|
To see the necessity of routine neck node dissection in micro PTC, we will compare the recurrence rate and other complication (e.g. hoarseness and hypocalcemia) between group I(no dissection) and group III(routine dissection) after completion of study(after 5 year f/u). To check the safety of this study, our result will be checked by korea institutional reveiw board every one year. |
Until 5 year follow-up. (Dec. 2016)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The efficacy of sentinel lymph node biopsy in micro PTC
Time Frame: Until 5 year follow-up. (Dec. 2016)
|
Until 5 year follow-up. (Dec. 2016)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jee Soo Kim, M.D., Ph.D., Samsung Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2009-02-017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.